British pharmaceutical company GlaxoSmithKline (GSK) has received European approval to market its treatment for endometrial cancer. The drug, Jemperli, will be used in combination with chemotherapy to treat patients with cancerous cells in their uterus. The European Commission granted marketing authorization for Jemperli in combination with carboplatin-paclitaxel for the treatment of adult patients with newly diagnosed or recurrent advanced endometrial cancer.
The decision to approve the drug was based on a study showing its positive effect on the “progression-free survival” of cancer and “overall survival”. Endometrial cancer is one of the most common cancers, with over 120,000 new cases annually in Europe. It typically affects postmenopausal women and develops in the inner lining of the uterus. While the prognosis for this cancer is relatively favorable compared to other female cancers, it still leads to numerous fatalities.
Jemperli has already been in use in France since October under an early access program, allowing certain patients to receive treatment that has not yet been formally authorized. This is a significant development in the treatment of endometrial cancer and provides hope for patients and healthcare professionals alike.
The approval of Jemperli in combination with chemotherapy is a positive step forward in the fight against endometrial cancer. GSK’s press release stated that the company is committed to providing innovative treatment options for patients with cancer. The approval of Jemperli in Europe brings hope to those affected by endometrial cancer and represents a major advancement in the field of oncology. This new drug combination has the potential to improve outcomes and provide new treatment options for patients with this type of cancer.
Source
Photo credit www.euronews.com
